Publications of François JOURET
Bookmark and Share    
Full Text
See detailIs autosomal dominant polycystic kidney disease an early sweet disease?
DACHY, Angélique ULiege; Decuypère, Jean-Paul; Vennekens, Rudi et al

in Pediatric Nephrology: Journal of the International Pediatric Nephrology Association (2022)

Detailed reference viewed: 32 (1 ULiège)
Full Text
See detailSerological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2.
Firket, Louis ULiege; Descy, Julie ULiege; Seidel, Laurence ULiege et al

in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2021), 21(11), 3806-3807

Grupper et al. have reported on a positive humoral response post full vaccination with mRNA SARS-CoV2 BNT162b2 in only 51/136 (37.5%) kidney transplant recipients (KTRs) without prior exposure to the ... [more ▼]

Grupper et al. have reported on a positive humoral response post full vaccination with mRNA SARS-CoV2 BNT162b2 in only 51/136 (37.5%) kidney transplant recipients (KTRs) without prior exposure to the virus(1) . We have conducted an IRB-approved (B707201215598-2021/80) prospective small sample-size study comparing the humoral response to BNT162b2 in 40 consecutive individuals early exposed to the Belgian vaccination program, including 20 KTRs with (n=10, COVID-19(+)) versus without (n=10, COVID-19(-)) history of exposure to SARS-CoV-2 and 20 controls including 10 COVID-19(+) versus 10 COVID-19(-). [less ▲]

Detailed reference viewed: 56 (7 ULiège)
Full Text
See detailMesenchymal stromal cells combined with everolimus promote Treg expansion but do not synergize in a rat liver transplant rejection model
VANDERMEULEN, Morgan ULiege; ERPICUM, Pauline ULiege; BLETARD, Noëlla ULiege et al

in Transplant International (2021, August), 34(S1 OP519), 101

Background: Mesenchymal stromal cells (MSCs) have particular properties that can be of interest in organ transplantation, including expansion of regulatory T cells (Tregs), a key factor in graft tolerance ... [more ▼]

Background: Mesenchymal stromal cells (MSCs) have particular properties that can be of interest in organ transplantation, including expansion of regulatory T cells (Tregs), a key factor in graft tolerance induction. The immunosuppression to be associated with MSCs has not yet been defined. Additionally, the impact of the association of everolimus with MSCs on Treg expansion and on induction of liver graft tolerance has never been studied. The aim of this study was to evaluate the effects of MSCs combined, or not, with everolimus, on Treg expansion and in a model of liver transplantation (LT) rejection in the rat. Methods: Firstly, Lewis rats received intravenous MSCs at D9 with/without subcutaneous everolimus from D0 to D14. Analysis of circulating Tregs was performed at D0, D14 and D28. Secondly, 48 h after LT with a Dark Agouti rat liver, 30 Lewis rats were randomized in 3 groups: everolimus (subcutaneous for 14 days), MSCs (intravenous injection at D2 and D9), or both everolimus and MSCs. Rejection of the liver graft was assessed by liver tests, histology and survival. Results: Individually, MSC infusion and everolimus promoted Treg expansion in rats, and everolimus had no negative impact on Treg expansion when combined with MSCs. However, in the LT model, injections of MSCs 2 and 9 days following LT were not effective at preventing acute rejection, and the combination of MSCs with everolimus failed to show any synergistic effect when compared to everolimus alone. Conclusion: Everolimus may be used in association with MSCs. However, in our model of LT in the rat, post-transplant MSC injections did not prevent acute rejection, and the association of MSCs with everolimus did not show any synergistic effect. [less ▲]

Detailed reference viewed: 22 (3 ULiège)
Full Text
See detailPerioperative risk factors of acute kidney injury post liver transplantation: a monocentric retrospective cohort study of 260 patients
Malisoux, Clarisse ULiege; KOCH, Jean-Noël ULiege; MEURISSE, Nicolas ULiege et al

in Transplant International (2021, August), 34(S1 POS315), 312

Aims and Background: Acute kidney injury (AKI) is a major risk factor of poor outcomes after liver transplantation (LT). AKI is usually attributed to post-LT events and drug toxicity. Peri-operative risk ... [more ▼]

Aims and Background: Acute kidney injury (AKI) is a major risk factor of poor outcomes after liver transplantation (LT). AKI is usually attributed to post-LT events and drug toxicity. Peri-operative risk factors of LT-associated AKI remain poorly documented, which hampers the development of personalized preventive strategies. Methods: AKI was assessed by KDIGO criteria based on creatinine changes from baseline to day 5 post LT. 260 single first full-size LTs without any pre-existing renal replacement therapy (RRT) were performed from 2003 to 2018. Incidence of AKI was assessed. Logistic regression determined the risk factors of KDIGO I and II-III AKI. Results: Incidence of AKI KDIGO I and II-III was 30% (78/260) and 25.7% (67/260), respectively. Preoperatively, patients with AKI had higher lab- MELD and Child-Pugh scores, lower serum fibrinogen and albumin levels. Donor type, donor hepatectomy and cold ischemic time were similar between groups. AKI was more frequent in case of marginal donors. LT surgery was longer in the AKI groups. Needs for per-operative blood transfusions were higher in the AKI groups. Rate of post-reperfusion syndrome was higher in AKI groups. Postoperatively, lower hemoglobin levels and higher INR from day 1-5 were associated with AKI. Peak of transaminases were not different between AKI versus non-AKI groups. AKI was associated with longer length of hospital and ICU stays. After multivariate analysis, blood transfusions and post-reperfusion syndrome were risk factors to develop KDIGO I AKI. Pre-operative serum levels of fibrinogen and albumin were risk factors for KDIGO II-III AKI. Finally, “marginal donors” was the only risk factor for both KDIGO I and II-III AKI. Conclusions: LT-associated AKI occurs in >50% of cases. Per-operative hemorrhage and post-operative reperfusion syndrome represent risk factors, particularly in cases of marginal donors. [less ▲]

Detailed reference viewed: 27 (2 ULiège)
Full Text
See detailHuman Stool Metabolome Differs upon 24 h Blood Pressure Levels and Blood Pressure Dipping Status: A Prospective Longitudinal Study
Cirillo, Arianna ULiege; Huart, Justine ULiege; Taminiau, Bernard ULiege et al

Poster (2021, May 26)

: Dysbiosis of gut microbiota (GM) has been involved in the pathophysiology of arterial hypertension (HT), via a putative role of short chain fatty acids (SCFAs). Its role in the circadian regulation of ... [more ▼]

: Dysbiosis of gut microbiota (GM) has been involved in the pathophysiology of arterial hypertension (HT), via a putative role of short chain fatty acids (SCFAs). Its role in the circadian regulation of blood pressure (BP), also called “the dipping profile”, has been poorly investigated. Sixteen male volunteers and 10 female partners were subjected to 24 h ambulatory BP monitoring and were categorized in normotensive (NT) versus HT, as well as in dippers versus non-dippers. Nuclear magnetic resonance (NMR)-based metabolomics was performed on stool samples. A 5-year comparative follow-up of BP profiles and stool metabolomes was done in men. Significant correlations between stool metabolome and 24 h mean BP levels were found in both male and female cohorts and in the entire cohort (R2 = 0.72, R2 = 0.79, and R2 = 0.45, respectively). Multivariate analysis discriminated dippers versus non-dippers in both male and female cohorts and in the entire cohort (Q2 = 0.87, Q2 = 0.98, and Q2 = 0.68, respectively). Fecal amounts of acetate, propionate, and butyrate were higher in HT versus NT patients (p = 0.027; p = 0.015 and p = 0.015, respectively), as well as in non-dippers versus dippers (p = 0.027, p = 0.038, and p = 0.036, respectively) in the entire cohort. SCFA levels were significantly different in patients changing of dipping status over the 5-year follow-up. In conclusion, stool metabolome changes upon global and circadian BP profiles in both genders [less ▲]

Detailed reference viewed: 36 (12 ULiège)
Full Text
See detailHuman Stool Metabolome Differs upon 24 h Blood Pressure Levels and Blood Pressure Dipping Status: A Prospective Longitudinal Study
HUART, Justine ULiege; Cirillo, Arianna ULiege; Taminiau, Bernard ULiege et al

in Metabolites (2021), 11(5), 282

Dysbiosis of gut microbiota (GM) has been involved in the pathophysiology of arterial hypertension (HT), via a putative role of short chain fatty acids (SCFAs). Its role in the circadian regulation of ... [more ▼]

Dysbiosis of gut microbiota (GM) has been involved in the pathophysiology of arterial hypertension (HT), via a putative role of short chain fatty acids (SCFAs). Its role in the circadian regulation of blood pressure (BP), also called "the dipping profile", has been poorly investigated. Sixteen male volunteers and 10 female partners were subjected to 24 h ambulatory BP monitoring and were categorized in normotensive (NT) versus HT, as well as in dippers versus non-dippers. Nuclear magnetic resonance (NMR)-based metabolomics was performed on stool samples. A 5-year comparative follow-up of BP profiles and stool metabolomes was done in men. Significant correlations between stool metabolome and 24 h mean BP levels were found in both male and female cohorts and in the entire cohort (R2 = 0.72, R2 = 0.79, and R2 = 0.45, respectively). Multivariate analysis discriminated dippers versus non-dippers in both male and female cohorts and in the entire cohort (Q2 = 0.87, Q2 = 0.98, and Q2 = 0.68, respectively). Fecal amounts of acetate, propionate, and butyrate were higher in HT versus NT patients (p = 0.027; p = 0.015 and p = 0.015, respectively), as well as in non-dippers versus dippers (p = 0.027, p = 0.038, and p = 0.036, respectively) in the entire cohort. SCFA levels were significantly different in patients changing of dipping status over the 5-year follow-up. In conclusion, stool metabolome changes upon global and circadian BP profiles in both genders. [less ▲]

Detailed reference viewed: 46 (11 ULiège)
Full Text
See detailThe faecal abundance of short chain fatty acids is increased in men with a non-dipping blood pressure profile
HUART, Justine ULiege; Cirillo, Arianna ULiege; SAINT-REMY, Annie ULiege et al

in Acta Cardiologica (2021)

Background and aims: Gut microbiota (GM) has been involved in the pathophysiology of hypertension (HT), notably via short chain fatty acids (SCFAs). Among the clinical manifestations of HT, the absence of ... [more ▼]

Background and aims: Gut microbiota (GM) has been involved in the pathophysiology of hypertension (HT), notably via short chain fatty acids (SCFAs). Among the clinical manifestations of HT, the absence of a significant drop in night-time blood pressure (BP) (also known as the non-dipping BP profile) has been associated with poor renal and cardiovascular outcomes. The putative link between GM-derived metabolites and BP dipping status is still unknown. Methods: Male volunteers (n ¼ 44) were prospectively subjected to 24-hour ambulatory blood pressure monitoring, stool sample collection and a medical questionnaire. Metabolomics analy ses of stool samples were conducted using Nuclear Magnetic Resonance (NMR). Results: Higher amounts of acetate, butyrate and propionate were found in the stools of non dippers (n ¼ 12) versus dippers (n ¼ 26) (p ¼ 0.0252, p ¼ 0.0468, and p ¼ 0.0496, respectively; n ¼ 38 in toto). NMR spectral data were not interpretable in 5 dippers and 1 non-dipper. A simi lar significant association was found when including only patients without anti-HT medications (p ¼ 0.0414, p ¼ 0.0108, and p ¼ 0.0602, respectively; n ¼ 21 in toto). A not significant trend was observed when focussing only on HT patients without anti-HT medications (p ¼ 0.0556; n ¼ 14 in toto). Conclusion: Our pilot study highlights a putative link between GM-derived SCFAs and the BP dipping status, independently of the BP status itself or the anti-hypertensive medications. [less ▲]

Detailed reference viewed: 38 (8 ULiège)
Full Text
See detailImmunosuppression Withdrawal After Liver Transplantation for Common Variable Immunodeficiency.
Detry, Olivier ULiege; MEURISSE, Nicolas ULiege; Jouret, François ULiege et al

in Liver Transplantation (2021), 27(3), 456-458

Detailed reference viewed: 40 (6 ULiège)
Full Text
See detailProteinuria in COVID‑19: prevalence, characterization and prognostic role
HUART, Justine ULiege; BOUQUEGNEAU, Antoine ULiege; Lutteri, Laurence ULiege et al

in Journal of Nephrology (2021), 34(3), 355-364

Abstract Background Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantifcation and characterization of ... [more ▼]

Abstract Background Proteinuria has been commonly reported in patients with COVID-19. However, only dipstick tests have been frequently used thus far. Here, the quantifcation and characterization of proteinuria were investigated and their association with mortality was assessed. Methods This retrospective, observational, single center study included 153 patients, hospitalized with COVID-19 between March 28th and April 30th, 2020, in whom total proteinuria and urinary α1-microglobulin (a marker of tubular injury) were measured. Association with mortality was evaluated, with a follow-up until May 7th, 2020. Results According to the Kidney Disease Improving Global Outcomes staging, 14% (n=21) of the patients had category 1 proteinuria (<150 mg/g of urine creatinine), 42% (n=64) had category 2 (between 150 and 500 mg/g) and 44% (n=68) had category 3 proteinuria (over 500 mg/g). Urine α1-microglobulin concentration was higher than 15 mg/g in 89% of patients. After a median follow-up of 27 [14;30] days, the mortality rate reached 18%. Total proteinuria and urinary α1-microglobulin were associated with mortality in unadjusted and adjusted models. This association was stronger in subgroups of patients with normal renal function and without a urinary catheter. Conclusions Proteinuria is frequent in patients with COVID-19. Its characterization suggests a tubular origin, with increased urinary α1-microglobulin. Tubular proteinuria was associated with mortality in COVID-19 in our restropective, observational study. [less ▲]

Detailed reference viewed: 77 (12 ULiège)
Full Text
See detailLong-term effects of COVID-19 on kidney function
DELANAYE, Pierre ULiege; HUART, Justine ULiege; BOUQUEGNEAU, Antoine ULiege et al

in Lancet (2021), 397(10287), 1807

Detailed reference viewed: 33 (1 ULiège)
Full Text
See detail[(18)F]FDG PET/CT imaging disproves renal allograft acute rejection in kidney transplant recipients with acute kidney dysfunction: a validation cohort.
LOVINFOSSE, Pierre ULiege; Weekers, Frédéric ULiege; Pottel, Hans ULiege et al

in European journal of nuclear medicine and molecular imaging (2021)

PURPOSE: [(18)F]FDG PET/CT may predict the absence of acute allograft rejection (AR) in kidney transplant recipients (KTRs) with acute kidney injury (AKI). Still, the proposed threshold of 1.6 of the mean ... [more ▼]

PURPOSE: [(18)F]FDG PET/CT may predict the absence of acute allograft rejection (AR) in kidney transplant recipients (KTRs) with acute kidney injury (AKI). Still, the proposed threshold of 1.6 of the mean of mean standardized uptake values (mSUVmean) in the renal parenchyma needs validation. METHODS: We prospectively performed 86 [(18)F]FDG PET/CT in 79 adult KTRs who underwent per-cause transplant biopsy for suspected AR. Biopsy-proven polyoma BK nephropathies (n = 7) were excluded. PET/CT was performed 192 ± 18 min after administration of 254.4 ± 30.4 MBq of [(18)F]FDG. The SUV(mean) was measured in both upper and lower poles of the renal allograft. One-way analysis of variance (ANOVA) and Tukey's studentized range test were sequentially performed. The receiver operating characteristic (ROC) curve was drawn to discriminate "AR" from non-pathological ("normal" + "borderline") conditions. RESULTS: The median age of the cohort was 55 [43; 63] years, with M/F gender ratio of 47/39. The mean eGFR was 31.9 ± 14.6 ml/min/1.73m(2). Biopsies were categorized in 4 groups: "normal" (n = 54), "borderline" (n = 9), "AR" (n = 14), or "others" (n = 2). The median [min; max] mSUV(mean) reached 1.72 [1.02; 2.07], 1.97 [1.55; 2.11], 2.13 [1.65, 3.12], and 1.84 [1.57; 2.12] in "normal," "borderline," "AR," and "others" groups, respectively. ANOVA demonstrated a significant difference of mSUV(mean) among groups (F = 13.25, p < 0.0001). The ROC area under the curve was 0.86. Test sensitivity and specificity corresponding to the threshold value of 1.6 were 100% and 30%, respectively. CONCLUSION: [(18)F]FDG PET/CT may help noninvasively prevent inessential transplant biopsies in KTR with AKI. [less ▲]

Detailed reference viewed: 52 (7 ULiège)
Full Text
See detailSystème rénine-angiotensine-aldostérone : bref historique et questionnements face à la pandémie COVID-19
VALDES SOCIN, Hernan Gonzalo ULiege; JOURET, François ULiege; VROONEN, Laurent ULiege et al

in Revue Médicale de Liège. Supplément (2020), 75

The breakthrough of the secrets of hypertension and the renin-angiotensin-aldosterone system (RAAS) is one of the legends of medicine. The first chapter is the one of Tigerstedt’s experiments about renin ... [more ▼]

The breakthrough of the secrets of hypertension and the renin-angiotensin-aldosterone system (RAAS) is one of the legends of medicine. The first chapter is the one of Tigerstedt’s experiments about renin, and Loesch and Gollblatt’s model of renal hypertension. The race to elucidate the mechanisms of angiotensin, angiotensinogen and the angiotensin conversion enzyme cascade, by Braun Menéndez and Page teams, is a second chapter. The puzzle of this elegant cascade is completed by aldosterone isolation by the collaboration of Tait spouses and Tadeus Rechstein. As a corollary of these findings, Conn made the first description of primary hyperaldosteronism. The elucidation of RAAS pathophysiology naturally led to the synthesis of the antihypertensive captopril by Ondetti and Cushman, thereby opening the modern era of ACE inhibitors and ARII blockers. In March 2020, a viral pandemic caused by SARS-Cov-2 ignites the entire planet. This new coronavirus uses the RAAS angiotensin conversion enzyme type 2 (ACE-2) as a gateway. The SARS-CoV-2/ ACE-2 signalling pathway and its pathological effects on the cardio-respiratory and renal system of these patients initiate a new chapter. The interaction of SARS-Cov-2/ ACE-2 axis with anti-hypertensive agents, as well as with ACE-2 activators and ACE-2 homologs, takes a part of an active international study searching for therapeutic targets. This modern research, summarized in this article, will further develop our knowledge of RAAS and, hopefully, will improve the management of COVID-19 patients. [less ▲]

Detailed reference viewed: 115 (18 ULiège)
Full Text
See detailImpact of mesenchymal stromal cells and/or everolimus on T-reg lymphocyte expansion in rats
Vandermeulen, Morgan ULiege; ERPICUM, Pauline ULiege; POMA, Laurence ULiege et al

Conference (2020, March 11)

Background: Mesenchymal stromal cells (MSC) are a promising cell-therapy in solid-organ transplantation, namely because of their immunomodulatory properties and positive impact on the expansion of T ... [more ▼]

Background: Mesenchymal stromal cells (MSC) are a promising cell-therapy in solid-organ transplantation, namely because of their immunomodulatory properties and positive impact on the expansion of T-regulator lymphocytes (Treg). The “optimal” immunosuppressive regimen to be associated with MSC has not been defined. Here, we aimed to evaluate the effects on Treg expansion of a single injection of MSC combined or not with everolimus in rats. Materials and methods: Twenty-four Lewis rats were randomly assigned to 4 groups (n=6 per group): MSC+Evero group, i.e. everolimus (0,25mg/kg/day, SC) from D0 to D14 and iv MSC (±1x106 cells) at D9; MSC group, i.e. placebo from D0 to D14 and iv MSC at D9; Evero group, i.e. everolimus from D0 to D14 and iv saline at D9; control group, i.e. placebo from D0 to D14 and iv saline at D9. T-reg blood levels were measured at D0-14-28 with flow cytometry analysis using anti-CD4,-CD25 and -FoxP3 antibodies. Results: In the two groups infused with MSC, Treg were significantly expanded at D14 and D28 (p<0.01), in comparison to D0. When compared to controls group, the “Evero” group showed a significant expansion of Treg levels at D14 but not at D28. In control, Treg levels did not significantly change compared to D0. Conclusion: A single iv MSC injection was efficient to expand T-reg blood levels. This effect was not altered by everolimus co-administration. Everolimus exposure alone promotes a transient T-reg expansion. Hence, everolimus may be regarded as a co-drug of choice in MSC-based therapy in solid-organ transplantion. [less ▲]

Detailed reference viewed: 43 (4 ULiège)
Full Text
See detailNouveautés thérapeutiques en Néphrologie : 10 ans d'avancées
BOVY, Christophe ULiege; DELANAYE, Pierre ULiege; JOURET, François ULiege et al

in Revue Médicale de Liège (2020), 75(5-6), 336-343

Chronic kidney disease (CKD) impairs the quality of life and increases the risk for cardiovascular morbimortality. Intensive research is conducted in order to slow down CKD development and progression ... [more ▼]

Chronic kidney disease (CKD) impairs the quality of life and increases the risk for cardiovascular morbimortality. Intensive research is conducted in order to slow down CKD development and progression. During the past decade, a better understanding of the pathophysiological mechanisms of glomerular diseases has highlighted the benefits of rituximab. Progresses have also been made in the understanding of the mechanisms of autosomal polycystic kidney disease, the most frequent inherited kidney disease. These observations led to the discovery and validation of tolvaptan, a blocker of the V2 receptor of the antidiuretic hormone as an innovative treatment. Type 2 diabetic disease is the leading cause worldwide of endstage kidney disease and dialysis. The development of new drugs, such as the gliflozins (inhibiting the sodium glucose reabsorption in the proximal tubule), has contributed to an improvement in the management of the cardiovascular and renal risks especially reducing congestive heart failure rate. Another important progress in nephrology since the beginning of the new century concerns a more precise estimation of the kidney function, which allows to better evaluate the slope of CKD progression and test the influence of different therapeutic approaches aiming at correcting anemia, hyperkalemia, metabolic acidosis and disturbances of calcium and phosphate. The present review summarizes all of these major advances in the field of CKD diagnosis and treatment, and envisions the future of nephrology for the next decade. [less ▲]

Detailed reference viewed: 230 (12 ULiège)
Full Text
See detailTargeting chloride transport in autosomal dominant polycystic kidney disease.
Jouret, François ULiege; Devuyst, Olivier

in Cellular Signalling (2020), 73

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited kidney disease. Transepithelial fluid secretion is one of the key factors of cystogenesis in ADPKD. Multiple studies ... [more ▼]

Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent inherited kidney disease. Transepithelial fluid secretion is one of the key factors of cystogenesis in ADPKD. Multiple studies have suggested that fluid secretion across ADPKD cyst-lining cells is driven by the secretion of chloride, essentially mediated by the CFTR channel and stimulated by increased intracellular levels of 3',5'-cyclic adenosine monophosphate. This review focuses on the pathophysiology of fluid secretion in ADPKD based on the pioneering studies of Jared Grantham and colleagues, and on the follow-up investigations from the molecular level to the potential applications in ADPKD patients. Altogether, the studies of fluid and chloride transport in ADPKD paved the way for innovative therapeutic targets to prevent cyst volume expansion and thus, kidney disease progression. [less ▲]

Detailed reference viewed: 54 (11 ULiège)
Full Text
See detailArgument en faveur d'un rôle du microbiote intestinal dans la physiopathologie de l'hypertension artérielle
HUART, Justine ULiege; KRZESINSKI, Jean-Marie ULiege; JOURET, François ULiege

in Revue Médicale de Liège (2020), 75(9), 588-592

The gut microbiota refers to the community of microorganisms living in the mammalian digestive tract. Over the past decades, numerous preclinical and clinical studies have suggested that gut microbiota is ... [more ▼]

The gut microbiota refers to the community of microorganisms living in the mammalian digestive tract. Over the past decades, numerous preclinical and clinical studies have suggested that gut microbiota is involved in the physiological homeostasis of the host, particularly in the immune and metabolic systems. Furthermore, the dysfunction of gut microbiota, also called “dysbiosis”, has been associated with various diseases, such as the metabolic syndrome or chronic kidney disease. In this review, we summarize the knowledge about the possible role of gut microbiota in the development of arterial hypertension. We detail the pathophysiological mechanisms, namely involving short-chain fatty acids produced by the bacterial fermentation of food carbohydrates. These metabolites are reabsorbed by the intestinal mucosa and interact with a multitude of G-protein coupled receptors at the surface of cells involved in blood pressure regulation, including renal tubular cells. These observations open up innovative diagnostic and therapeutic approaches in arterial hypertension, which is a major public health problem. [less ▲]

Detailed reference viewed: 128 (2 ULiège)
Full Text
See detailAtteintes rénales de la COVID-19
ERPICUM, Pauline ULiege; GROSCH, Stéphanie ULiege; BOUQUEGNEAU, Antoine ULiege et al

in Revue Médicale de Liège. Supplément (2020), 75(supplément 1), 109-114

The SARS-CoV-2 virus causes a respiratory distress syndrome, the main symptom of COVID-19 (for “COronaVIrus Disease 2019”). This infectious disease has been causing a major health and socio-economic ... [more ▼]

The SARS-CoV-2 virus causes a respiratory distress syndrome, the main symptom of COVID-19 (for “COronaVIrus Disease 2019”). This infectious disease has been causing a major health and socio-economic pandemic since December 2019. The pulmonary alveolus is regarded as the main target of SARS-CoV-2. However, this coronavirus is capable of directly or indirectly affecting other organs, including the kidneys. Here, we summarize the presumed pathophysiology of COVID-19 renal disease. The incidence of acute kidney injury ranges from 0,5 to 22 % of all patients infected with SARS-CoV-2. The need for renal replacement therapy is reported in 5-9 % of patients in intensive care. Histological analysis of renal biopsies mainly shows acute tubular necrosis of varying severity, as well as the congestion of glomerular and peri-tubular capillaries. Endothelitis has been described in few cases. Evidence for a factual inflammation of the glomerulus remains controversial. The medium/long term consequences of COVID-19 nephropathy are unknown and will deserve a tight follow-up. [less ▲]

Detailed reference viewed: 469 (19 ULiège)
Full Text
See detailImplications of early diagnosis of autosomal dominant polycystic kidney disease: A post hoc analysis of the TEMPO 3:4 trial.
Janssens, Peter; Jouret, François ULiege; Bammens, Bert et al

in Scientific Reports (2020), 10(1), 4294

It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3 ... [more ▼]

It is unknown whether early diagnosis of autosomal dominant polycystic kidney disease (ADPKD) can enable earlier management and improve outcomes. We conducted a post hoc analysis of data from the TEMPO 3:4 trial. Subjects were stratified by ADPKD diagnosis at age </=18 (childhood diagnosis [CD]) or>18 (adulthood diagnosis [AD]). Groups were compared for baseline characteristics and total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline over 3 years. 294 CD and 1148 AD subjects were analyzed. At inclusion, CD subjects were younger (mean age 34.2 versus 39.8 years; p < 0.0001) and had better eGFR (mean +/- SD 87.4 +/- 23.9 versus 80.1 +/- 20.7 mL/min/1.73 m(2); p < 0.0001), while CD had more severe Mayo risk classification (p < 0.0001) and more PKD1 mutations (p = 0.003). No statistical differences were found in TKV or eGFR change. At study end, placebo-treated CD subjects had better eGFR than projected by a prediction equation (mean difference +/-SD for observed versus predicted eGFR: 2.18 +/- 10.7 mL/min/1.73 m(2); p = 0.0475). However, these results are not confirmed when excluding stage 1 CKD. Whether CD subjects, despite their risk profile, have a slower disease course than predicted remains inconclusive. Future studies are needed to confirm that early diagnosis and management can alter the disease course of ADPKD. [less ▲]

Detailed reference viewed: 46 (5 ULiège)